Shanghai Yihao Biotechnology Co., Ltd. is located in Shanghai Juke Biological Park. It is committed to becoming a practitioner in the field of cell therapy in China, regarding “improving innovative tumor immunotherapy technology” as a concept, an attitude, and a kind of pursuit in order to provide a cutting-edge and accurate treatment plan for cancer patients.More
Stem cells and their derivatives have been known as revolutions in medical history in the 21st century...
The research and development of Yihao's biological tumor immune cell therapy is at the forefront...
To date, the U.S. Food & Drug Administration (FDA) has approved two forms of CAR T cell therapy for patients with non-Hodgkin lymphoma. City of Hope is one of the only institutions in the United State
Just a month after approving the first cancer therapy that uses genetically engineered immune cells collected from patients, the Food and Drug Administration (FDA) has now cleared a second such therap
Join UCLA pediatric oncologist Satiro De Oliveira, MD, for a discussion about CAR T-cell therapy for pediatric patients, including indications, plan of care, side effects, risks and benefits.